This post was originally published on this site Janssen has submitted an application to Japanese authorities seeking the approval of Darzalex (daratumumab) — in combination with standard Revlimid (lenalidomide) and dexamethasone — for the treatment of newly diagnosed multiple myeloma patients ineligible for high-dose chemotherapy and stem cell transplant. The supplemental new drug application, which will be considered under priority review, is based on data from…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
Age, Obesity, Comorbidities Linked with Severe Fatigue Among Non-Hodgkin’s Lymphoma Survivors
This post was originally published on this site While a significant proportion of non-Hodgkin’s lymphoma survivors suffer from severe fatigue, the type of initial treatment and Rituxan (rituxumab) use did not influence this outcome, a new study shows. Instead, severe fatigue was found to be correlated with increased age, obesity, and the presence of other comorbidities.…
Living In-between
This post was originally published on this site I have been a follicular lymphoma patient since 2008. One of the strangest things about this disease is the kind of “in-between-ness” that it can put some patients into. You’re not really cured, but you’re not really sick, either. (Terrilyn McCormick writes about this very well.) You…
Early Phase 3 Trial Results of Tedopi for Advanced NSCLC Are Positive
This post was originally published on this site Early results from the ATALANTE-1 Phase 3 trial indicate that Tedopi benefits people with advanced non-small cell lung cancer (NSCLC) who failed to respond to prior checkpoint inhibitor therapy, OSE Immunotherapeutics reported. Three enrolled patients responded positively to third-line treatment with Tedopi, either achieving a partial reduction…
Surgery Extends Lives of Women with Metastatic Breast Cancer, Study Says
This post was originally published on this site Women with HER2-positive breast cancer that has spread to distant organs live longer if they have surgery to remove their primary tumor, according to research presented at the recent American Association for Cancer Research (AACR) Annual Meeting 2019 in Atlanta, Georgia. The findings were featured on the…
ADXS-PSA/Keytruda Combo Prolongs Survival in mCRPC, Early Trial Results Suggest
This post was originally published on this site Adding ADXS-PSA, an investigational cancer vaccine, to Keytruda (pembrolizumab) is showing positive signs of safety and efficacy in patients with metastatic, castration-resistant prostate cancer (mCRPC), and appears to prolong survival compared with standard-of-care therapy, early results from an ongoing Phase 1/2 trial show. The results were announced…
Phase 1 Trial of CA-4948 Recruiting Non-Hodgkin’s Lymphoma Patients
This post was originally published on this site A Phase 1 clinical trial is recruiting relapsed or refractory non-Hodgkin’s lymphoma patients to determine the safest and most effective dose of the oral therapy CA-4948. The trial is now treating patients in its fifth dosing group, Curis announced. CA-4948, developed by Curis in collaboration with Aurigene, is a small molecule that works by…
Web-based PREDICT Prostate Tool Provides Personalized Cancer Prognosis
This post was originally published on this site A new web-based tool, called PREDICT Prostate, incorporates patients’ clinical and demographic data to provide a personalized prognosis to men with prostate cancer, helping them choose between radical treatment or watchful waiting. The online tool was launched the same day the results of the study, “Individual prognosis…
Viome and Helomics Team Up to Study Possible Links Between Gut Microbiome and Ovarian Cancer
This post was originally published on this site With the aim of advancing personalized therapy, a pilot study will investigate a possible correlation between gut microbiome and ovarian cancer. The investigation is the initial development of a new partnership between Viome, whose proprietary gut microbiome test is used to personalize diet and nutrition recommendations, and…
Investigational Ygalo Shows Promise for Relapsed or Refractory Multiple Myeloma, Interim Data Show
This post was originally published on this site Ygalo (melflufen), a novel compound under investigation for relapsed and refractory multiple myeloma, was well-tolerated and demonstrated promising signs of high efficacy in two global clinical trials conducted by Oncopeptides. The data was presented April 1–2 at this year’s American Association for Cancer Research Annual Meeting, held in…
Nonprofit Organizations Pair Up During Sarcoidosis Awareness Month
This post was originally published on this site The American Lung Association and Foundation for Sarcoidosis Research are working together during April’s Sarcoidosis Awareness Month to offer U.S. sarcoidosis patients and caregivers additional support, making available in-person support groups and online tutorials by specialists. As part of the activities of Sarcoidosis Awareness Month, the associations…
First CTCL Patients Enrolled in Phase 2 Trial of Topical Treatment WP1220
This post was originally published on this site The Phase 2 clinical trial assessing Moleculin Biotech‘s STAT3 inhibitor, WP1220, for the topical treatment of cutaneous T-cell lymphoma (CTCL) lesions has enrolled the first two participants. The trial, to assess WP1220‘s safety and efficacy, has been reviewed and approved by regulatory authorities in Poland, where the study will be conducted.…